overlapping silhouettes of male and female heads

Source: Pixabay/geralt

Hazardous hormones & the heart

How being transgender affects cardiac health

Transgender individuals may be at higher risk for myocardial infarction and death due to cardiovascular disease, according to several studies. This increased risk may be due to the hormone therapy that transgender patients take for masculinization or feminization. A review authored by Michael S. Irwig, MD, associate professor of medicine at the George Washington University (GW) School of Medicine and Health Sciences and director of the Andrology Center at the GW Medical Faculty Associates, examined several studies that followed transgender individuals on hormone therapy.

In clinical studies that followed transgender patients, rates for myocardial infarction were consistently higher in transgender women on estrogen therapy than in transgender men on testosterone

Michael S. Irwig

“Many transgender patients take either testosterone or estrogen for masculinization or feminization,” explained Irwig. “Some studies have suggested that transgender people have an increased risk for heart attack and death due to cardiovascular disease.” The review focuses on cardiovascular events (myocardial infarction, stroke and venous thromboembolism) and surrogate markers — including blood pressure and lipid concentrations — in transgender patients on hormone therapy who may or may not have undergone gender affirmation procedures. The studies that the review covers show that transgender women appear to have increased risk for cardiovascular events due to hormone therapy whereas the data is unclear for transgender men. It is well known that estrogen therapy for trans women increases their risk of blood clots (deep venous thromboses).

Recommended article

Photo

Lesbian, gay, bi, trans

Should all patients be asked about their sexual orientation?

In late 2017, NHS England released guidelines recommending that health professionals ask all patients about their sexual orientation in order to improve services for non-heterosexual patients, but should they? Experts debate the issue in The BMJ today. After decades of campaigning from lesbian, gay, bisexual and trans (LGBT) charities, sexual orientation is now a protected characteristic that is…

“In clinical studies that followed transgender patients, rates for myocardial infarction were consistently higher in transgender women on estrogen therapy than in transgender men on testosterone,” Irwig said. “The relationship between endogenous sex hormones and heart disease is complex. In cisgender women, estrogen may have a protective effect.”

Given that hormone therapy is often essential in the management of transgender patients, Irwig suggests that more research is needed on the effects and risk of hormone therapy in older transgender populations and on the safest forms of estrogen therapy.

The review, titled “Cardiovascular Health in Transgender People,” is published in Reviews in Endocrine and Metabolic Disorders.


Source: George Washington University

03.08.2018

Read all latest stories

Related articles

Cardiology congress

ESC 2018: At the heart of research

When delegates from around 150 countries converge on Munich for ESC Congress 2018 they will no doubt reflect on what they themselves eat. Yes, nutrition is up for debate, questioning, for example,…

Cardiology

Do our hearts beat digital or analog?

Scientists at the Virginia Tech Carilion Research Institute (VTCRI) have found evidence that may disrupt conventional understanding about how electrical activity travels in the heart — a discovery…

Sodium consumption

Daily salt intake: How much is too much for our heart?

New research shows that for the vast majority of individuals, sodium consumption does not increase health risks except for those who eat more than five grams a day, the equivalent of 2.5 teaspoons of…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH